Sustained quality-of-life improvement post-cryoballoon ablation in patients with paroxysmal atrial fibrillation: Results from the STOP-AF Post-Approval Study.
| Autor: | Jain SK; UPMC Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: jainsk@upmc.edu., Novak PG; University of British Columbia Royal Jubilee Hospital, Victoria, BC, Canada., Sangrigoli R; Doylestown Cardiology Associates, Doylestown, Pennsylvania., Champagne J; Quebec Heart Institute, Quebec City, QC, Canada., Dubuc M; Montreal Heart Institute, Montreal, QC, Canada., Adler SW; HealthEast Heart Care, St. Paul, Minnesota., Svinarich JT; Colorado Heart and Vascular, Denver, Colorado., Essebag V; McGill University Health Center, Division of Cardiology, Montréal, QC, Canada., Martien M; Medtronic, Mounds View, Minnesota., Anderson C; Medtronic, Mounds View, Minnesota., John RM; Vanderbilt University, Nashville, Tennessee., Mansour M; Massachusetts General Hospital, Boston, Massachusetts., Knight BP; Northwestern University, Chicago, Illinois. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Heart rhythm [Heart Rhythm] 2020 Mar; Vol. 17 (3), pp. 485-491. Date of Electronic Publication: 2019 Oct 10. |
| DOI: | 10.1016/j.hrthm.2019.10.014 |
| Abstrakt: | Background: Pulmonary vein isolation by catheter ablation is a class IA indication for the treatment of symptomatic, drug-refractory, paroxysmal atrial fibrillation (PAF). Quality of life (QoL) has been identified as a clinically meaningful endpoint but has not been comprehensively evaluated to date. Objective: The purpose of this study was to evaluate the effects of cryoballoon ablation on long-term QoL. Methods: As part of the STOP-AF Post-Approval Study, QoL was assessed using the Short Form-12 Health Survey (SF-12) along with evaluation of arrhythmia-related symptoms through 36 months. A multivariate linear mixed effects regression was used to determine the association between atrial fibrillation symptoms and QoL scores, and univariate linear regressions were used to assess predictors of 36-month change in QoL scores. Results: Three hundred thirty-five subjects fully completed SF-12 forms at baseline, with 319, 308, 291, and 278 subjects completing surveys at the subsequent follow-up visits. Both physical and mental composite scores increased significantly from baseline (P <.001), and all arrhythmia symptoms significantly decreased from baseline (P <.001), with 62.0% of subjects reporting no symptoms at 6 months compared to 5.7% at baseline (P <.001). Presence of dyspnea and fatigue at baseline were univariate predictors of physical QoL improvement (P = .045 and 0.0497, respectively), whereas each year of age and each year of PAF duration were predictors of a decrease in mental QoL (P = .014 and .04, respectively). Conclusion: Cryoballoon ablation for treatment of PAF results in a significant, and sustained, QoL improvement. The observed improvement in physical and mental health likely may be mediated by a reduction in symptom and arrhythmia burden. (Copyright © 2019 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|